Boston Scientific Aktie
| 99,12USD | -1,63USD | -1,62% |
WKN: 884113 / ISIN: US1011371077
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 38 000 | 41 000 | 45 000 | 48 000 | 53 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,26 | 0,29 | 0,28 | 0,30 | 0,32 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 6 694 | 6 317 | 5 760 | 6 514 | 6 920 |
| Summe Anlagevermögen | 24 083 | 25 912 | 26 709 | 28 622 | 32 475 |
| Summe Aktiva | 30 777 | 32 229 | 32 469 | 35 136 | 39 395 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 15 450 | 15 607 | 14 896 | 15 606 | 17 392 |
| Summe Eigenkapital | 15 327 | 16 622 | 17 573 | 19 530 | 22 003 |
| Summe Passiva | 30 777 | 32 229 | 32 469 | 35 136 | 39 395 |
Adresse
| 300 Boston Scientific Way, 01752-1234 Marlborough | |
| Telefon | +1 (508) 683-4000 |
| Internet | http://www.bostonscientific.com |
Management
|
Arthur Crosswell Butcher
EVP, Group President-MedSurg & Asia Pacific |
|
Charles J. Dockendorff
Independent Director |
|
Charlie Attlan
SVP-New Business Development, Strategy & Portfolio |
|
Cheryl Pegus
Director |
|
Colin Morrison
Director-Business Development & Venture Capital |
|
Daniel J. Brennan
Chief Financial Officer & Executive Vice President |
|
David C. Habiger
Director |
|
David Scott Wichmann
Independent Director |
|
Edward J. Ludwig
Lead Independent Director |
|
Ellen M. Zane
Independent Director |
|
Emily Woodworth
Chief Accounting Officer, SVP & Controller |
|
Eric Francis Yves Thepaut
EVP, President-Europe, Middle East & Africa |
|
Jeffrey B. Mirviss
President-Peripheral Interventions & Executive VP |
|
Jessica L. Mega
Independent Director |
|
Jim Cassidy
Vice President & Franchise Lead-Pain Management |
|
Jodi Eddy
Senior VP, Chief Information & Digital Officer |
|
John Bradley Sorenson
Executive Vice President-Global Operations |
|
John Edward Sununu
Independent Director |
|
Jonathan Richard Monson
Senior Vice President-Investor Relations |
|
Joseph M. Fitzgerald
President-Cardiology & Executive Vice President |
|
June Chang
President-Greater China |
|
Kathryn Graves Unger
Vice President-Environmental, Social & Governance |
|
Kenneth Stein
Global Chief Medical Officer & Senior VP |
|
Mark Bickel
VP-Finance & Global Controller-Rhythm Management |
|
Mary Beth Moynihan
Chief Marketing Officer & Senior VP-Market Access |
|
Meghan M. Scanlon
President-Urology & Senior Vice President |
|
Michael F. Mahoney
Chairman, President & Chief Executive Officer |
|
Michael Jones
President-Endoscopy & Senior Vice President |
|
Milad Girgis
Vice President & Franchise Lead |
|
Miriam O’Sullivan
Chief Human Resources Officer & Senior VP |
|
Nicholas Spadea-Anello
President-Electrophysiology & Senior VP |
|
Rosaleen Burke
Senior Vice President-Global Quality & Regulatory |
|
Samuel Conaway
President-US Sales Cardiology Group |
|
Susan E. Morano
Independent Director |
|
Susan J. Thompson
Chief Corporate Counsel, VP & Assistant Secretary |
|
Vance Ronald Brown
Secretary, Senior Vice President & General Counsel |
|
Yoshiaki Fujimori
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.